• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Study suggests multiple-drug resistance in canine hookworm an emerging problem

June 24, 2020
Sarah Mouton Dowdy
dvm360, dvm360 July 2020, Volume 51, Issue 7

According to the findings of a new study, the rise and spread of resistant Ancylostoma caninum isn’t just bad news for dogs. It may be a sign of what’s to come for human hookworm infections as well.

Although it’s the most prevalent intestinal nematode parasite in dogs in the United States, Ancylostoma caninum (canine hookworm) has historically been well controlled with the anthelmintic drugs febantel, moxidectin, milbemycin oxime, fenbendazole and pyrantel. However, parasitologists from several U.S. veterinary colleges have reported an uptick in infection recurrence within the past three years—mostly in greyhounds, but in other breeds as well—which suggests the parasite may have become resistant to the drugs typically used to control it. A group of researchers led by Pablo D. Jimenez Castro, DVM, from the University of Georgia College of Veterinary Medicine, set out to study the validity of this hunch.1

What they did

Dr. Castro and his team obtained fecal samples from three dogs (a greyhound, a miniature schnauzer and a hound mix) being treated for persistent hookworm infections, as well as from two infected dogs with no history of treatment with anthelmintics. Hookworm eggs from these samples were used to infect laboratory beagles and to perform egg hatch assays (to detect resistance to benzimidazoles) and larval development assays (to detect resistance to macrocyclic lactones). These assays were also conducted on eggs taken from the laboratory-infected research dogs.

Advertisement

To detect pyrantel resistance, three of the infected research dogs (representing two isolates) were treated with the anthelmintic drug and then fecal egg count reductions were measured. Finally, using DNA extracted from pools of eggs, third-stage larvae or adults, the researchers used deep amplicon sequencing assays to measure the frequency of nonsynonymous single nucleotide polymorphisms at three different codons (167, 198 and 200) of the A. caninum isotype β-tubulin gene.

What they found

When compared with the dogs with no history of anthelmintic treatments, the A. caninum isolates taken from the three dogs with suspected drug resistance had resistance ratios ranging from 6 to more than 100 for the egg hatch assay and from 5.5 to 69.8 for the larval development assay. As for the two isolates treated with pyrantel, one of the egg counts had no change and the other actually increased. Moreover, a high frequency of resistance-associated single nucleotide polymorphisms was identified at codon 167 in the three resistant isolates.

What this means (for dogs and humans)

According to the researchers, this study’s findings “conclusively demonstrate multiple anthelmintic resistance in multiple independent isolates of A. caninum, strongly suggesting that this is an emerging problem in the United States.” They go on to describe the findings as “important and concerning,” as the rise and spread of canine hookworms that are resistant to the three main anthelmintic classes—the only effective drug classes currently approved for the treatment of canine hookworms in the U.S.—could seriously threaten canine health.

But according to the researchers, dogs aren’t the only animals in danger. The study notes that if anthelmintic resistance can arise in canine hookworms, human medicine should take notice because A. caninum is phylogenetically similar to the hookworm species of humans (A. duodenale, A. ceylanicum and Necator americanus). And as the researchers explain, “the scale-up of mass drug administration for soil-transmitted helminths is now placing similar selection pressures for benzimidazole resistance on human hookworms and reduced efficacies are widely reported.” They offer that the deep amplicon sequencing assay from the study could be used to monitor worldwide benzimidazole resistance in human hookworms.

Reference

  1. Jimenez Castro PD, Howell SB, Schaefer JJ, et al. Multiple drug resistance in the canine hookworm Ancylostoma caninum: an emerging threat? Parasit Vectors. 2019;12(1):576.

Sarah Mouton Dowdy, a former associate content specialist for dvm360.com, is a freelance writer and editor in Kansas City, Missouri.

download issueDownload Issue: dvm360 July 2020

Related Content:

MedicalAssociatesTechniciansClinicalParasitologyRolesdvm360 July 2020
Can our Pride panel answer these LGBTQ+ trivia questions?
Can our Pride panel answer these LGBTQ+ trivia questions?
Creating inclusive spaces for the LGBTQ+ community in vet med
Creating inclusive spaces for the LGBTQ+ community in vet med
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

Advertisement

Latest News

Humanimal Trust joins World Federation for Animals

News wrap-up: This week’s headlines, plus Kansas State University College of Veterinary Medicine presents Temple Grandin, PhD, MS, with an honorary degree

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

View More Latest News
Advertisement